RAI14 and breast fibrocystic disease: Thus, we included breast cancer (BC) patients, benign breast disease (BBD) patients and healthy controls in this study to evaluate the prevalence of RAI14 in breast cancer and its correlation with the clinicopathological parameters of patients to determine whether RAI14 can be considered as a serum marker for TNBC and as such be applied in the clinical diagnosis of TNBC along with CA15-3.